BOCA RATON, Fla., June 18, 2015 — Biotest Pharmaceuticals Corporation (BPC), a leading developer of immunological biotherapeutic products, is pleased to announce the relocation of its plasma collection center to 6000 Mahoning Avenue, Suite 410, in Youngstown, Ohio. The 15,165 square foot state-of-the-art facility officially opened its doors for business on Sunday, June 14, 2015.
“This facility relocation represents our continued commitment to better serve our donors who help the thousands of patients world-wide who rely on plasma-based therapies by strengthening our network of plasma collection centers,” said Jordan Siegel, BPC’s Chief Executive Officer.
The plasma donated at Biotest Plasma Centers is used to manufacture critical care therapies that treat life-threatening disorders in a variety of therapeutic areas, such as BPC’s BIVIGAM® [Immune Globulin Intravenous (Human), 10% Liquid] and Nabi-HB® [Hepatitis B Immune Globulin (Human)].
The Company expects this newly relocated facility to expand its current workforce to over 50 employees and currently has employment opportunities available for medical personnel and phlebotomists.
In addition to supporting the local economy through employment opportunities, the plasma center is actively recruiting local residents to donate plasma. Plasma donors not only contribute the source material for these plasma-derived therapies that save the lives of thousands of patients but also are compensated for their donations.
Important Safety Information for BIVIGAM® [Immune Globulin Intravenous (Human), 10% Liquid]
BIVIGAM® [Immune Globulin Intravenous (Human), 10% Liquid] is indicated for the treatment of primary humoral immunodeficiency (PI). This includes, but is not limited to, the humoral immune defect in common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.
Warning: Thrombosis may occur with immune globulin intravenous (IGIV) products, including BIVIGAM®. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, a history of venous or arterial thrombosis, the use of estrogens, indwelling vascular catheters, hyperviscosity and cardiovascular risk factors. Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with the administration of Immune Globulin Intravenous (Human) (IGIV) products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. BIVIGAM does not contain sucrose. For patients at risk of thrombosis, renal dysfunction, or renal failure, administer BIVIGAM at the minimum dose recommended and infusion rate practicable. Ensure adequate hydration in patients before administrations. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for viscosity.
See full Prescribing Information for complete boxed warning.
About Biotest Pharmaceuticals Corporation
Biotest Pharmaceuticals is a wholly-owned subsidiary of Biotest AG, a German global provider of plasma products. The Company researches, develops and manufactures biotherapeutic plasma protein products, with a specialization in immunology and hematology and is a leader in the collection of source plasma. Biotest Pharmaceuticals owns and manages plasmapheresis centers across the United States and operates a state-of-the-art manufacturing facility in Boca Raton, Florida. We are committed to serving the thousands of patients worldwide who rely on plasma-based therapies.
Biotest Pharmaceuticals’ team of over 1000 employees is part of Biotest AG’s global workforce of more than 2,300 associates worldwide. To learn more about Biotest Pharmaceuticals, our Plasma Centers, and the difference we make in the lives of patients and the healthcare community, please visit us at www.biotestpharma.com and www.biotestplasma.com.